Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07386418

Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds

Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07386418.

📅 26 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07386418
Sponsor
Imperial College London
Start
2026-02-10
ClinicaliQ Trial Snapshot
  • Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07386418.
  • What is being tested: ORBITA-SOLAR investigates whether individual coronary stenoses have unique angina thresholds by measuring the specific degree of coronary flow reduction needed to reproduce symptoms during invasive catheterisation in 60 symptomatic patients.
  • Patient eligibility overview: The study enrolls patients with symptomatic coronary artery disease undergoing invasive cardiac catheterisation who have identifiable coronary stenoses suitable for physiological assessment.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time,…

Eligibility Snapshot
  • : 1. Eligibility for PCI due to angina or angina-equivalent symptoms on exertion 2. 2 severe epicardial stenoses in a major coronary artery, defined as: 1. ≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA) 2. Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA 3. Evidence of ischaemia on an invasive or non-invasive test, including: 1. Physiological test during invasive coronary angiography (ICA) 2. Dobutamine stress echocardiography (DSE) 3. Stress perfusion cardiac magnetic resonance (CMR) 4. Myocardial perfusion scintigraphy (MPS) 5. Fractional flow reserve computed-tomography (FFR-CT)

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Cardiology / Cardiovascular · 30 Mar 2026
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →
Guideline
2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
Cardiology / Cardiovascular · 30 Mar 2026
Covers risk stratification for sudden cardiac death and indications for ICD implantation • Provides management recommendations for ventricular tachycardia and ventricular fibrillation…
View guideline →
Guideline
2024 ESC Guidelines for the Management of Atrial Fibrillation
Cardiology / Cardiovascular · 30 Mar 2026
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →